Newborn infants have little or no secretory IgA (SIgA) at birth ... No study to date has examined SIgA production as a function of gestational age or examined the kinetics of SIgA acquisition ...
Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine, a ...
Secretory IgA is resistant to degradation and provides ... Postnatal maternal immunizations aimed to enhance breast milk antibodies production might be a promising approach. In addition to being ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...
Select Phase 1/2 Study Results Patients with IgA nephropathy (IgAN ... About ARO-C3 ARO-C3 is designed to reduce hepatocyte production of complement component 3 (C3) as a potential treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results